David Shaw’s UroGen Pharma URGN Stock Holding History

David Shaw’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42.2M	Buy	1,145,819 +122,660	+12%	+$3.32M	0.02%	847
2026 Q1	$18.4M	Buy	1,023,159 +60,535	+6%	+$1.21M	0.01%	1209
2025 Q4	$22.5M	Buy	962,624 +73,691	+8%	+$1.6M	0.01%	1173
2025 Q3	$17.7M	Buy	888,933 +861,501	+3,140%	+$15.5M	0.01%	1262
2025 Q2	$376K	Buy	+27,432	New	+$263K	﹤0.01%	3764
2024 Q3	–	Sell	-10,843	Closed	-$182K	–	4911
2024 Q2	$182K	Buy	+10,843	New	+$154K	﹤0.01%	4092
2024 Q1	–	Sell	-77,873	Closed	-$1.17M	–	4762
2023 Q4	$1.17M	Buy	77,873 +44,240	+132%	+$574K	﹤0.01%	3039
2023 Q3	$471K	Buy	+33,633	New	+$540K	﹤0.01%	3449

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

David Shaw's URGN Position: Q2 2026 in Review

David Shaw increased its UroGen Pharma (URGN) stake by 12% in Q2 2026, buying an estimated $3.32M and bringing the position to 1,145,819 shares worth $42.2M. The position accounts for 0.02% of the portfolio, ranked #847.

David Shaw first reported a position in URGN in Q3 2023 and has held it in 8 quarters since. 188 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

David Shaw held 1,145,819 shares of UroGen Pharma worth $42.2M as of Q2 2026.
David Shaw bought 122,660 UroGen Pharma shares in Q2 2026, an estimated $3.32M.
UroGen Pharma made up 0.02% of David Shaw's portfolio in Q2 2026, its #847 holding.
David Shaw first reported a position in UroGen Pharma in Q3 2023 and has held it in 8 quarters since.
188 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.